LMAT vs NHC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LMAT exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and exceptional liquidity, but it is currently facing a severe valuation disconnect. While the company shows strong growth (41.4% earnings growth) and high gross margins, the current price of $114.62 significantly exceeds both the Graham Number ($31.3) and the growth-based Intrinsic Value ($74.34). This premium is further complicated by heavy insider selling, including a large divestment by the CEO, and a bearish technical trend despite the price being near 52-week highs.
NHC exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a nearly debt-free balance sheet (Debt/Equity 0.08). While the stock trades below its growth-based intrinsic value of $226.26, it is currently priced above its defensive Graham Number of $108.96. The outlook is tempered by a concerning Forward P/E of 403.00 and a streak of four consecutive earnings misses, suggesting a significant projected decline in profitability. Despite strong long-term price appreciation, the current technical trend is heavily bearish (10/100), indicating a potential short-term reversal or consolidation phase.
Compare Another Pair
Related Comparisons
LMAT vs NHC: Head-to-Head Comparison
This page compares LeMaitre Vascular, Inc. (LMAT) and National HealthCare Corporation (NHC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.